Pharmafile Logo

Gower Publishing

Virtual Speaker Program: A Customer Story

Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions.

Impetus Digital

- PMLiVE

Eli Lilly to acquire Protomer Technologies in a deal worth over $1bn

Protomer Technologies is a US biotech company focused on engineering glucose-responsive insulin

- PMLiVE

FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm

Leaders maintain that Aduhelm fits into the regulatory paradigm of the FDA’s accelerated approval pathway

- PMLiVE

FDA questions safety profile of AZ, FibroGen’s anaemia drug roxadustat

AZ and FibroGen are aiming for approval of roxadustat in anaemia caused by chronic kidney disease

- PMLiVE

Wearing masks to remain compulsory on London transport after restrictions are eased

Announcement comes ahead of Prime Minister Boris Johnson’s plans to relax most COVID-19 restrictions in England on 19 July

- PMLiVE

FDA lists rare neurological condition as potential side effect of J&J’s COVID-19 vaccine

Guillain-Barré syndrome has been reported in 100 people who have received the vaccine in the US

- PMLiVE

Researchers publish promising results for ultra-rare disease gene therapy method

Gene therapy method evaluated in seven children with aromatic amino acid decarboxylase deficiency

Biogen Idec building

Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

Orelabrutinib is currently being evaluated in a phase 2 trial in relapsing-remitting MS

- PMLiVE

World Mask Week campaigners encourage continued mask wearing to help slow the spread of COVID-19

The campaign is encouraging both individuals and organisations to support continued mask wearing

- PMLiVE

Novo Nordisk signs deal for Prothena’s heart drug worth up to $1.2bn

Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy

- PMLiVE

Philip Morris International to acquire inhaled drug company Vectura for $1.2bn

Vectura is developing inhaled drug delivery solutions for a number of diseases including COVID-19

- PMLiVE

FDA acting commissioner Janet Woodcock requests independent review of Aduhelm approval

Approval of Biogen's Alzheimer's disease treatment has raised concerns over FDA staff interactions with the company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links